TY - JOUR
T1 - Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma
AU - Osoba, D.
AU - Aaronson, N. K.
AU - Muller, M.
AU - Sneeuw, K.
AU - Hsu, M. A.
AU - Yung, W. K.A.
AU - Brada, M.
AU - Newlands, E.
N1 - Funding Information:
We are grateful to Ms. Cynthia Gelke and Dr. Christine Meyers (MD Anderson Cancer Center) and Ms. Helen A. Evans (Charing Cross Hospital), Ms. Sue Sardell and Mr. Douglas Guerrero (Royal Marsden Hospital) for administration of the questionnaires and collecting the data; to Dr. David Sugano and Dr. Margaret Dugan (Schering-Plough Co.) for their contributions to the study and to Ms. Heena Vadgama and Ms. Jill Vardy for assembling the manuscript. Financial support was provided by Schering-Plough Co., Kenilworth, N.J.
PY - 1997
Y1 - 1997
N2 - The purpose of the study was to assess health-related quality of life (HQL) in patients with high-grade malignant glioma of the brain. The EORTC core Quality of Life Questionaire (QLQ-C30) and a Brain Cancer Module (BCM20) were administered at baseline and several weeks later (follow-up) to 105 patients with either recently-diagnosed (n = 41) or recurrent (n = 64) malignant glioma. In addition, the attending neurologists completed a standard neurological examination, a modified Barthel Activities of Daily Living Index (BADLI) and the Karnofsky Performance Scale (KPS). In a preliminary step, the QLQ-C30 was found to have acceptable reliability (internal consistency and test-retest reliability). Newly-diagnosed patients and those with a KPS of 80-100 had significantly better physical, role and cognitive functioning and global quality of life with less fatigue, visual disorder, motor dysfunction, communication deficit, weakness of both legs and trouble controlling the bladder than did those with recurrent disease and those with a KPS of 50-70. Similarly, those capable of independent activities of daily living, as reported on the BADLI, had higher functioning scores and less fatigue than did those who were not independent. Patients with dysphasia, mental confusion or motor deficit on neurological examination reported significantly lower levels of physical, role, cognitive, emotional and social functioning and global quality of life than did patients not having these difficulties. They also had significantly more symptoms. In patients with deteriorating neurological status between baseline and follow-up, there was a marked decline in cognitive, physical, role, emotional and social functioning and global quality of life and an increase in fatigue. Thus, there are significant differences in HQL between patients with newly-diagnosed and recurrent brain cancer and between patients with differing KPS and BADLI scores. In addition, the HQL scores provide details not provided by the KPS and the BADLI. Deterioration in neurological function is accompanied by significant deterioration in a range of HQL domains and in global quality of life.
AB - The purpose of the study was to assess health-related quality of life (HQL) in patients with high-grade malignant glioma of the brain. The EORTC core Quality of Life Questionaire (QLQ-C30) and a Brain Cancer Module (BCM20) were administered at baseline and several weeks later (follow-up) to 105 patients with either recently-diagnosed (n = 41) or recurrent (n = 64) malignant glioma. In addition, the attending neurologists completed a standard neurological examination, a modified Barthel Activities of Daily Living Index (BADLI) and the Karnofsky Performance Scale (KPS). In a preliminary step, the QLQ-C30 was found to have acceptable reliability (internal consistency and test-retest reliability). Newly-diagnosed patients and those with a KPS of 80-100 had significantly better physical, role and cognitive functioning and global quality of life with less fatigue, visual disorder, motor dysfunction, communication deficit, weakness of both legs and trouble controlling the bladder than did those with recurrent disease and those with a KPS of 50-70. Similarly, those capable of independent activities of daily living, as reported on the BADLI, had higher functioning scores and less fatigue than did those who were not independent. Patients with dysphasia, mental confusion or motor deficit on neurological examination reported significantly lower levels of physical, role, cognitive, emotional and social functioning and global quality of life than did patients not having these difficulties. They also had significantly more symptoms. In patients with deteriorating neurological status between baseline and follow-up, there was a marked decline in cognitive, physical, role, emotional and social functioning and global quality of life and an increase in fatigue. Thus, there are significant differences in HQL between patients with newly-diagnosed and recurrent brain cancer and between patients with differing KPS and BADLI scores. In addition, the HQL scores provide details not provided by the KPS and the BADLI. Deterioration in neurological function is accompanied by significant deterioration in a range of HQL domains and in global quality of life.
KW - BCM20
KW - Brain cancer
KW - Karnofsky Performance Status
KW - QLQ-C30
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=0030761590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030761590&partnerID=8YFLogxK
U2 - 10.1023/A:1005790632126
DO - 10.1023/A:1005790632126
M3 - Article
C2 - 9258818
AN - SCOPUS:0030761590
SN - 0167-594X
VL - 34
SP - 263
EP - 278
JO - Journal of neuro-oncology
JF - Journal of neuro-oncology
IS - 3
ER -